PortalPublikationenMonkeypox Virus Cross-Neutralizing Antibodies in Clinical Tr...

Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein

Standard

Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein. / Raadsen, Matthijs P; Dahlke, Christine; Fathi, Anahita; Lamers, Mart M; van den Doel, Petra; Zaeck, Luca M; van Royen, Martin E; de Bruin, Erwin; Sikkema, Reina; Koopmans, Marion; van Gorp, Eric Cm; Sutter, Gerd; de Vries, Rory D; Addo, Marylyn M; Haagmans, Bart L.

in: J INFECT DIS, Jahrgang 228, Nr. 5, 31.08.2023, S. 586-590.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Raadsen, MP, Dahlke, C, Fathi, A, Lamers, MM, van den Doel, P, Zaeck, LM, van Royen, ME, de Bruin, E, Sikkema, R, Koopmans, M, van Gorp, EC, Sutter, G, de Vries, RD, Addo, MM & Haagmans, BL 2023, 'Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein', J INFECT DIS, Jg. 228, Nr. 5, S. 586-590. https://doi.org/10.1093/infdis/jiad052

APA

Raadsen, M. P., Dahlke, C., Fathi, A., Lamers, M. M., van den Doel, P., Zaeck, L. M., van Royen, M. E., de Bruin, E., Sikkema, R., Koopmans, M., van Gorp, E. C., Sutter, G., de Vries, R. D., Addo, M. M., & Haagmans, B. L. (2023). Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein. J INFECT DIS, 228(5), 586-590. https://doi.org/10.1093/infdis/jiad052

Vancouver

Raadsen MP, Dahlke C, Fathi A, Lamers MM, van den Doel P, Zaeck LM et al. Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein. J INFECT DIS. 2023 Aug 31;228(5):586-590. https://doi.org/10.1093/infdis/jiad052

Bibtex

@article{6fd3b7a14c90421bb6417c4ca17204b9,
title = "Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein",
abstract = "Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)-associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.",
keywords = "Antibodies, Neutralizing, Antibodies, Viral, Broadly Neutralizing Antibodies, Coronavirus Infections/prevention & control, Humans, Middle East Respiratory Syndrome Coronavirus, Monkeypox virus, Spike Glycoprotein, Coronavirus, Vaccinia virus/genetics, Viral Vaccines",
author = "Raadsen, {Matthijs P} and Christine Dahlke and Anahita Fathi and Lamers, {Mart M} and {van den Doel}, Petra and Zaeck, {Luca M} and {van Royen}, {Martin E} and {de Bruin}, Erwin and Reina Sikkema and Marion Koopmans and {van Gorp}, {Eric Cm} and Gerd Sutter and {de Vries}, {Rory D} and Addo, {Marylyn M} and Haagmans, {Bart L}",
note = "{\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.",
year = "2023",
month = aug,
day = "31",
doi = "10.1093/infdis/jiad052",
language = "English",
volume = "228",
pages = "586--590",
journal = "J INFECT DIS",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein

AU - Raadsen, Matthijs P

AU - Dahlke, Christine

AU - Fathi, Anahita

AU - Lamers, Mart M

AU - van den Doel, Petra

AU - Zaeck, Luca M

AU - van Royen, Martin E

AU - de Bruin, Erwin

AU - Sikkema, Reina

AU - Koopmans, Marion

AU - van Gorp, Eric Cm

AU - Sutter, Gerd

AU - de Vries, Rory D

AU - Addo, Marylyn M

AU - Haagmans, Bart L

N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

PY - 2023/8/31

Y1 - 2023/8/31

N2 - Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)-associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.

AB - Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)-associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.

KW - Antibodies, Neutralizing

KW - Antibodies, Viral

KW - Broadly Neutralizing Antibodies

KW - Coronavirus Infections/prevention & control

KW - Humans

KW - Middle East Respiratory Syndrome Coronavirus

KW - Monkeypox virus

KW - Spike Glycoprotein, Coronavirus

KW - Vaccinia virus/genetics

KW - Viral Vaccines

U2 - 10.1093/infdis/jiad052

DO - 10.1093/infdis/jiad052

M3 - SCORING: Journal article

C2 - 36857443

VL - 228

SP - 586

EP - 590

JO - J INFECT DIS

JF - J INFECT DIS

SN - 0022-1899

IS - 5

ER -